Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor implicated in multiple cancer hallmarks.
• STAT3 dysregulation drives tumor proliferation, metastasis, angiogenesis, immunosuppression, and metabolic reprogramming.
• Its critical role makes STAT3 a highly promising therapeutic target across diverse cancer types.

Purpose of the Study:

• To provide an up-to-date review of STAT3 signaling in cancer.
• To summarize STAT3 modulators, regulated cancer hallmarks, and its role in the tumor microenvironment and metabolism.
• To discuss current and emerging strategies for targeting STAT3 in cancer therapy.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on STAT3 signaling and its inhibitors.
• Analysis of STAT3's role in cancer hallmarks, immunosuppression, and metabolic reprogramming.
• Exploration of novel therapeutic strategies and combination therapies involving STAT3 inhibitors.

Main Results:

• STAT3 is involved in nearly all cancer hallmark processes, including proliferation, metastasis, and drug resistance.
• STAT3 exhibits complex regulation of immunosuppression and metabolic reprogramming within the tumor microenvironment.
• Numerous direct and indirect STAT3 inhibitors have shown promise in preclinical and clinical settings.

Conclusions:

• STAT3 is a pivotal mediator of cancer progression and a validated therapeutic target.
• Targeting STAT3, particularly through combination therapies, holds significant potential for improving cancer treatment outcomes.
• Further research into novel STAT3-targeting strategies may offer new perspectives for effective cancer therapy.